Adzynma

During treatment, allergic hypersensitivity reactions, including anaphylactic reactions, may occur.‍‍‍‍‍‍​​​‍​​​​​​ Patients should be informed of possible early symptoms, such as tachycardia, chest tightness, wheezing and/or sudden dyspnoea, hypotension, generalised urticaria, pruritus, rhinitis and conjunctivitis, angioedema, somnolence, nausea, vomiting, paraesthesia, or anxiety. In some cases, these symptoms may progress to anaphylactic shock. In the event of severe allergic reactions, administration of the medicinal product should be discontinued immediately and appropriate supportive treatment initiated. As with other therapeutic proteins, the use of apadamtase alfa carries a potential risk of immunogenicity. Patients may develop antibodies directed against rADAMTS13, which may lead to a diminished clinical response to treatment. If the presence of antibodies is suspected and the therapy is ineffective, alternative treatment options should be considered.